BioHarvest Sciences Q2 rev up 41% to $8.5mln, driven by VINIA and new products.

• BioHarvest Sciences reports Q2 2025 revenue up 41% YoY to $8.5mln • Core VINIA capsule business drives 80% of growth • New products contribute 20% growth • Gross profit increases 65% to $5.7mln • Digital data not mentioned in the article

BioHarvest Sciences Inc. (NASDAQ: BHST) has reported robust financial results for the second quarter of 2025, with revenue up 41% year-over-year to $8.5 million. The company's core VINIA capsule business drove 80% of the growth, while new products contributed 20% [1].

The increase in revenue was driven by a combination of factors, including the continued success of the VINIA family of products and the launch of the VINIA Daily Chews 2X Formula. Gross profit also increased significantly, rising 65% to $5.1 million, or 60% of total revenue [1].

BioHarvest's CDMO (Contract Development and Manufacturing Organization) business unit continues to contribute to revenue growth, with the company securing a new Stage 1 CDMO contract to develop a plant-based fragrance compound. The company also announced its first CDMO project to reach Stage 2, successfully validating the botanical synthesis platform for a variety of molecule types [1].

Looking ahead, BioHarvest expects third quarter 2025 revenues of at least $9.1 million and expects to reach adjusted EBITDA breakeven in the fourth quarter of 2025. The company plans to launch three growth initiatives in the second half of 2025, including a new health professional affiliate program, electrolyte drinks, and an AI-enabled CDMO discovery phase [1].

Despite the strong performance, BioHarvest reported a net loss of $4.0 million for the second quarter of 2025, primarily due to non-cash finance expenses associated with exchange rate impact [1].

References:
[1] https://www.biospace.com/press-releases/bioharvest-sciences-reports-second-quarter-2025-financial-results